AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients

MT Newswires Live12-12

AstraZeneca (AZN) and Merck & Co. (MRK) said Wednesday that updated results from a phase 3 trial of Lynparza showed that the drug demonstrated a prolonged survival benefit in early breast cancer patients.

Data showed that Lynparza provided "clinically meaningful" improvements in overall survival, invasive disease-free survival, and distant disease-free survival at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, the companies said.

The companies added that 87.5% of patients treated with Lynparza were alive at six years compared with 83.2% in the placebo group. The drug's safety and tolerability profile in the study was consistent with prior clinical trials and no new safety signals were identified during the longer follow-up.

Lynparza is being jointly developed and commercialized by AstraZeneca and Merck & Co.

Price: 67.55, Change: +0.37, Percent Change: +0.55

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment